Spots Global Cancer Trial Database for Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Official Title: A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Study ID: NCT06062420
Conditions
Study Description
Brief Summary: The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, New Haven, Connecticut, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Iowa City, Iowa, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Saint Louis, Missouri, United States
GSK Investigational Site, Omaha, Nebraska, United States
GSK Investigational Site, Columbus, Ohio, United States
GSK Investigational Site, Milwaukee, Wisconsin, United States
GSK Investigational Site, Capital Federal, Buenos Aires, Argentina
GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site, Florida, Buenos Aires, Argentina
GSK Investigational Site, Ciudad Autónoma de Buenos Aires, , Argentina
GSK Investigational Site, Cordoba, , Argentina
GSK Investigational Site, Mendoza, , Argentina
GSK Investigational Site, San Juan, , Argentina
GSK Investigational Site, Santa Fe, , Argentina
GSK Investigational Site, Santo Andre, Sao Paulo, Brazil
GSK Investigational Site, São Paulo, , Brazil
GSK Investigational Site, São Paulo, , Brazil
GSK Investigational Site, São Paulo, , Brazil
GSK Investigational Site, Calgary, Alberta, Canada
GSK Investigational Site, Edmonton, Alberta, Canada
GSK Investigational Site, Toronto, Ontario, Canada
GSK Investigational Site, Toronto, Ontario, Canada
GSK Investigational Site, Montreal, Quebec, Canada
GSK Investigational Site, Herlev, , Denmark
GSK Investigational Site, Turku, , Finland
GSK Investigational Site, Bordeaux Cedex, , France
GSK Investigational Site, Caen Cedex 5, , France
GSK Investigational Site, Marseille, , France
GSK Investigational Site, Paris, , France
GSK Investigational Site, Rouen, , France
GSK Investigational Site, Saint Herblain, , France
GSK Investigational Site, Villejuif Cedex, , France
GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany
GSK Investigational Site, Regensburg, Bayern, Germany
GSK Investigational Site, Frankfurt, Hessen, Germany
GSK Investigational Site, Giessen, Hessen, Germany
GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany
GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany
GSK Investigational Site, Leipzig, Sachsen, Germany
GSK Investigational Site, Berlin, , Germany
GSK Investigational Site, Hamburg, , Germany
GSK Investigational Site, Athens, , Greece
GSK Investigational Site, Haidari, Athens, , Greece
GSK Investigational Site, Thessaloniki, , Greece
GSK Investigational Site, Thessaloniki, , Greece
GSK Investigational Site, Gyor, , Hungary
GSK Investigational Site, Kecskemét, , Hungary
GSK Investigational Site, Nyíregyháza, , Hungary
GSK Investigational Site, Pécs, , Hungary
GSK Investigational Site, Szolnok, , Hungary
GSK Investigational Site, Napoli, Campania, Italy
GSK Investigational Site, Bologna, Emilia-Romagna, Italy
GSK Investigational Site, Roma, Lazio, Italy
GSK Investigational Site, Roma, Lazio, Italy
GSK Investigational Site, Genova, Liguria, Italy
GSK Investigational Site, Milano, Lombardia, Italy
GSK Investigational Site, Rozzano (MI), Lombardia, Italy
GSK Investigational Site, Novara, Piemonte, Italy
GSK Investigational Site, Bari, Puglia, Italy
GSK Investigational Site, Firenze, Toscana, Italy
GSK Investigational Site, Padova, Veneto, Italy
GSK Investigational Site, Aichi, , Japan
GSK Investigational Site, Chiba, , Japan
GSK Investigational Site, Hyogo, , Japan
GSK Investigational Site, Osaka, , Japan
GSK Investigational Site, Saitama, , Japan
GSK Investigational Site, Shizuoka, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Daegu-si, , Korea, Republic of
GSK Investigational Site, Seongnam-si, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Oslo, , Norway
GSK Investigational Site, Bielsko-Biala, , Poland
GSK Investigational Site, Gliwice, , Poland
GSK Investigational Site, Koszalin, , Poland
GSK Investigational Site, Krakow, , Poland
GSK Investigational Site, Poznan, , Poland
GSK Investigational Site, Przemysl, , Poland
GSK Investigational Site, Siedlce, , Poland
GSK Investigational Site, Warszawa, , Poland
GSK Investigational Site, Almada, , Portugal
GSK Investigational Site, Lisboa, , Portugal
GSK Investigational Site, Porto, , Portugal
GSK Investigational Site, Porto, , Portugal
GSK Investigational Site, Pitesti, Arges, Romania
GSK Investigational Site, Brasov, , Romania
GSK Investigational Site, Bucharest, , Romania
GSK Investigational Site, Bucharest, , Romania
GSK Investigational Site, Bucharest, , Romania
GSK Investigational Site, Bucuresti, , Romania
GSK Investigational Site, Bucuresti, , Romania
GSK Investigational Site, Craiova, , Romania
GSK Investigational Site, Craiova, , Romania
GSK Investigational Site, Floresti, , Romania
GSK Investigational Site, Iasi, , Romania
GSK Investigational Site, Oradea, , Romania
GSK Investigational Site, Suceava, , Romania
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Jaén, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Pozuelo De Alarcón/Madrid, , Spain
GSK Investigational Site, Salamanca, , Spain
GSK Investigational Site, Santander, , Spain
GSK Investigational Site, Valencia, , Spain
GSK Investigational Site, Zaragoza, , Spain
GSK Investigational Site, Stockholm, , Sweden
GSK Investigational Site, Changhua, , Taiwan
GSK Investigational Site, Tainan, , Taiwan
GSK Investigational Site, Taipei City, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Ankara, , Turkey
GSK Investigational Site, Antalya, , Turkey
GSK Investigational Site, Istanbul, , Turkey
GSK Investigational Site, İzmir, , Turkey
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
